©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Retinoid X Receptor Acts as a Hormone Receptor in Vivo to Induce a Key Metabolic Enzyme for 1,25-Dihydroxyvitamin D(*)

(Received for publication, July 11, 1995; and in revised form, August 4, 1995)

Elizabeth A. Allegretto (1)(§) Nirupama Shevde (2) Aihua Zou (1) Stanley R. Howell (3) Marcus F. Boehm (4) Bruce W. Hollis (5) J. Wesley Pike (1)

From the  (1)Departments of Biochemistry, (2)Transcription Research, (3)Drug Safety and Disposition, and (4)Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, California 92121 and the (5)Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

We demonstrate here that RNA levels of 25-hydroxyvitamin D(3)-24-hydroxylase (24-(OH)ase), a key catabolic enzyme for 1,25-dihydroxyvitamin D(3), are increased by a highly selective retinoid X receptor (RXR) ligand, LG100268, in mice within hours. Correspondingly, upon LG100268 treatment, kidney 24-(OH)ase enzymatic activity increases 5-10-fold. The endogenous retinoid hormones, all-trans-retinoic acid and 9-cis-retinoic acid, and the synthetic retinoic acid receptor-selective compound, TTNPB, also stimulate 24-(OH)ase. Additionally, we show that LG100268 stimulates transcription of a luciferase reporter plasmid driven by 24-(OH)ase promoter sequences in the presence of RXR in CV-1 cell cotransactivation assays. This first demonstration of a gene that is regulated in the intact animal through an RXR-mediated pathway confirms earlier hypotheses that RXR is a bona fide hormone receptor. Regulation of a key gene in the vitamin D signaling pathway by a retinoid transducer may provide a molecular basis for some of the documented biological effects of vitamin A on bone and vitamin D metabolism.


INTRODUCTION

Retinoic acid receptors (RARs) (^1)have been shown to act as hormone receptors by virtue of the fact that they bind all-trans-retinoic acid (tRA) with high affinity and activate target genes in the presence of tRA in cell-based cotransactivation assays and in vivo (reviewed in (1) ). Retinoid X receptors (RXRs) are also thought to act as hormone receptors (reviewed in (1) ) since they bind 9-cis-retinoic acid (9cRA) with high affinity (2, 3) and have been shown to stimulate transcription from distinct elements known as RXR-responsive elements in promoter sequences of the apolipoprotein A1 (apoA1) and cellular retinol-binding protein II (CRBPII) genes in cell-based cotransactivation assays in response to 9cRA(2, 3) , tRA(4, 5) , or RXR-selective ligands(6, 7) . However, these genes have not been shown to be regulated by retinoids in vivo. While another gene product (growth hormone) has been shown to increase in cultured cells treated with RXR- and RAR-selective ligands(8) , there are currently no known biological target genes of RXR in the intact animal.

RXRs are thought to form homodimers upon interaction with ligand (1) to activate putative RXR-selective genes, such as CRBPII and apoA1, through RXR-responsive elements in the promoters of those genes(2, 3, 4, 5, 6, 7) . RXR is also known to participate in heterodimers with a number of other intracellular receptors, including the vitamin D receptor (VDR), RAR, or thyroid hormone receptor to activate a variety of target genes, which are stimulated by 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)), tRA, or thyroid hormone, respectively(1) . RXR is thought to act as a silent partner in these interactions, although the effects of liganding of RXR under these circumstances have not been thoroughly explored. Additionally, recent studies describe instances of stimulation of gene transcription by hormone-occupied RXR interacting with a supposedly unoccupied orphan receptor(9, 10) .

To study the consequences of liganding of RXR in vivo, we began by testing the effects that an RXR-selective compound might have on the activity of a vitamin D-inducible gene. 25-Hydroxyvitamin D(3)-24-hydroxylase (24-(OH)ase) is one such gene product that is induced by 1,25-(OH)(2)D(3)(11) , acting through VDR-RXR heterodimers that bind to a vitamin D response element within the promoter of the gene(12, 13) . The effects of in vivo administration of various retinoids on the levels of the 24-(OH)ase gene product were examined. We found that RXR-selective ligands are able to stimulate 24-(OH)ase RNA levels and enzymatic activity within hours in normal or vitamin D-deficient mice. These results describe a novel RXR-target gene, which is also the first demonstration of such a gene in the intact animal.


EXPERIMENTAL PROCEDURES

Compounds

9cRA, LG100268(14) , and TTNPB were synthesized and purified at Ligand Pharmaceuticals, Inc. tRA (Schweizerhall, Inc.) was repurified at Ligand Pharmaceuticals, Inc.

Dosing of Mice

BALB/c female mice (Harlan-Teklad, 8-12 weeks old, three to four per dosing group) were placed on a control diet (low phosphate, low calcium; Harlan Teklad 94326) or a diet that renders them 1,25-(OH)(2)D(3)-deficient (minus vitamin D, low phosphate, low calcium, 0.8% strontium(15) ; Harlan Teklad 94325) for 14 days prior to dosing with compounds (Fig. 2) in sesame oil vehicle by oral gavage. Dosing for the 8-day experiment (Fig. 2a) was once daily in the a.m., and sacrifice was 3-4 h after the dose on the 8th day. The 32-h study (Fig. 2b) included drug doses that were at 8 a.m., noon, and 4 p.m. on the 1st day and 8 a.m. and noon on the 2nd day with sacrifice 3 h later. For 8-h studies (Fig. 3, Table 1and Table 2) mice were fed a normal diet (Harlan-Teklad 7012), and dosing was performed twice 4 h apart; sacrifice was 3-4 h after the last dose.


Figure 2: Effects of 1,25-(OH)(2)D(3) and retinoid treatment of vitamin D-deficient mice on kidney 24-(OH)ase RNA levels. Panel a, 20 µg of total kidney RNA from female Balb/c mice fed a normal diet treated with sesame oil vehicle (lanes 1-3) or from mice fed a diet that renders them 1,25-(OH)(2)D(3)-deficient, treated with vehicle (D-def veh, lanes 4-6), with 0.25 µg/kg 1,25-(OH)(2)D(3) (lanes 7-9), 0.25 µg/kg 1,25-(OH)(2)D(3) plus 30 mg/kg LG100268 (lanes 10-12), or with 30 mg/kg LG100268 (lanes 13-16) for 8 days with once daily doses. Panel b, 20 µg of total kidney RNA from mice fed a normal diet treated with vehicle (lanes 1-3) or mice fed a vitamin D-deficient diet treated with either vehicle (lanes 4-6), 0.25 µg/kg 1,25-(OH)(2)D(3) (lanes 7-9), 30 mg/kg LG100268 (lanes 13-15), or with 0.25 µg/kg 1,25-(OH)(2)D(3) in combination with 30 mg/kg LG100268 (lanes 10-12) for 32 h with 5 doses. Blots were hybridized with r24-(OH)ase and hGAPDH probes. Average-fold induction was determined by comparison of quantitated bands from drug-treated vitamin D-deficient groups with those of the vehicle-treated vitamin D-deficient groups.




Figure 3: Effects of retinoid treatment of normal fed mice on 24-(OH)ase, RARbeta, apoA1, and CRBPII expression. Mice (three to four per dosing group) were treated with two doses 4 h apart by oral gavage in sesame oil; sacrifice occurred 3 h after the last dose. Twenty µg of kidney (panela), 30 µg of kidney (panel b), 20 µg of liver (panelc, lanes 1-16), or 20 µg of intestine (panelc, lanes 17-24) total RNA was subjected to Northern analyses. Mice were treated with sesame oil vehicle (a and b, lanes 1-4, lanes 17-19; c, lanes 1-4, 17, 21), LG100268 (a and b, lanes 5-8; lanes 20-22; c, lanes 5-8, 18, 22), 9cRA (a and b, lanes 9-12; lanes 23-25; c, lanes 9-12, 19, 23), tRA (a and b, lanes 13-16; c, lanes 13-16, 20, 24), or TTNPB (a, lanes 26-28). Blots were hybridized with the indicated probes. Loading was equivalent in all lanes in panelc (GAPDH hybridization not shown).







Northern Analysis

RNA was extracted(16) , and Northern analyses were performed as by standard techniques. Probes were as follows: 900-bp EcoRI/XbaI DNA fragment of the rat 24-(OH)ase cDNA in pUC-r24-(OH)ase(11) ; 1.4-kb human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) fragment (Clonetech); RARbeta probe, a 1.4-kb NcoI/SacI fragment from YEpTRPhRARbeta, a yeast expression vector constructed using hRARbeta cDNA(17) ; apoA1 probe, a polymerase chain reaction-generated rat 142-bp PstI/HindIII fragment from pGEM-rApoA1 (18) ; mCRBPII probe, a 400-bp polymerase chain reaction product(19) ; and mouse beta-actin probe, a 1.5-kb EcoRI/XhoI fragment from pBLU-mbeta-actin (Stratagene). Quantitation was by PhosphorImager analysis (Molecular Dynamics).

Circulating Levels of Compounds

Plasma concentrations of LG100268 and 9cRA following dosing were determined using reversed phase high pressure liquid chromatography (HPLC). Equal volumes of plasma from three mice were combined to produce each 0.5-ml sample. 9cRA determination was as described previously(20) . LG100268 determination was as follows. Samples were precipitated with 5 volumes of methanol and then subjected to solid phase extraction. Solvent was evaporated, and the residue was solubilized in mobile phase (acetonitrile, 10 mM ammonium acetate, acetic acid (75:25:1)). Analyses were conducted using a Rainin Microsorb-MV C-18 column (250 times 4.6 mm) and an Alltech direct connect guard column maintained at 40 °C. Detection was at 281 nm, and the flow rate was 1.2 ml/min. The response of the instrument was linear between 0.25 and 25 µM.

Enzyme Activity Studies

Mice were dosed twice daily (4 h between doses) with 3 mg/kg LG100268 or vehicle for 8 h or 3.5 days (eight mice per group). Sacrifice was 3 h after the last dose. Kidneys were perfused with cold 0.25 M sucrose in phosphate-buffered saline, pH 7.4, pooled from four mice, homogenized, and precipitates were prepared as described previously(21) ; incubations (0.5 ml; 12 mg/ml protein) with 50 µM 25-(OH)D(3) were for 1 h at 37 °C(21) . Purification and quantitation of generated 24,25-(OH)(2)D(3) were by solid phase extraction and HPLC(21) .

Cotransactivation Assays

Cotransfection/transactivation assays were performed in CV-1 cells as described previously(2, 22) .


RESULTS AND DISCUSSION

Mice were treated with the RXR-selective compound, LG100268 (Fig. 1), a documented highly specific, high affinity binder and activator of RXRs(14) , and kidney 24-(OH)ase RNA levels were monitored by Northern analysis ( Fig. 2and 3). Vitamin D-deficient mice were treated with 1,25-(OH)(2)D(3) or vehicle with and without LG100268. After an 8-day regimen with once daily doses, 1,25-(OH)(2)D(3)-treated mice exhibited increased levels of kidney 24-(OH)ase RNA (6-fold), as expected (11) (Fig. 2a, lanes 7-9) versus vehicle-treated mice (Fig. 2a, lanes 4-6). LG100268 in combination treatment with 1,25-(OH)(2)D(3) resulted in an almost complete inhibition (Fig. 2a, lanes 10-12) of the increase in RNA levels that was observed with 1,25-(OH)(2)D(3) alone (Fig. 2a, lanes 7-9). Surprisingly, LG100268 treatment alone resulted in a 2-fold increase in 24-(OH)ase RNA levels (Fig. 2a, lanes 13-16) in comparison with the vitamin D-deficient mice that received vehicle (Fig. 2a, lanes 4-6). Interestingly, the effect of LG100268 to repress 1,25-(OH)(2)D(3) induction of 24-(OH)ase RNA observed after 8 days of treatment was not observed after dosing periodically for 32 h (Fig. 2b, lanes 10-12) in comparison with 1,25-(OH)(2)D(3)-treated mice (Fig. 2b, lanes 7-9). However, the induction of 24-(OH)ase RNA by LG100268 alone was observed at 32 h (Fig. 2b, lanes 13-15), and the -fold induction was greater (3.3-fold) than the 2-fold induction seen at 8 days (Fig. 2a, lanes 13-16). Since the repression effect of LG100268 on 1,25-(OH)(2)D(3) induction of 24-(OH)ase occurred only after longer time periods, a direct negative effect of the RXR ligand on the ability of the VDR-RXR heterodimer to stimulate 24-(OH)ase seemed unlikely. An alternate possibility might be that liganded RXR does not heterodimerize with VDR; complete depletion of the pool of unliganded RXR available to VDR may take longer than 32 h. However, since LG100268 induces 24-(OH)ase RNA in the absence of 1,25-(OH)(2)D(3) at both short and long time periods, it may also act via a VDR-independent mechanism to stimulate 24-(OH)ase. Since 24-hydroxylation is the initial enzymatic step in the catabolism of 1,25-(OH)(2)D(3), increased 24-(OH)ase activity over time might be expected to result in lower cellular concentrations of 1,25-(OH)(2)D(3) and, therefore, less VDR activity on its target genes, including 24-(OH)ase.


Figure 1: Structure of LG100268. The chemical name is 6-[1(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]nicotinic acid.



To test this hypothesis we set out to determine whether the induction of 24-(OH)ase by LG100268 also occurred in the non-vitamin D-deficient state. Mice were fed a normal diet and treated with LG100268 and various other retinoids. TTNPB, a known RAR-selective ligand of high potency(23, 24) , was tested to determine if the retinoid effect on 24-(OH)ase was limited to RXR-selective ligands. Mice were also treated with 9cRA and tRA to determine if the increased levels of 24-(OH)ase RNA observed upon treatment with the synthetic RXR-selective compound could also be elicited by the naturally occurring endogenous retinoid hormones. Three- to five-fold increases in kidney 24-(OH)ase RNA levels were detected from mice treated for a period of 8 h with two doses (spaced 4 h apart) of LG100268, 9cRA, or tRA in comparison with vehicle-treated mice (Fig. 3a, lanes 1-25). While no increase was detected with the potent RAR-selective ligand TTNPB at 1 µg/kg (data not shown), TTNPB at 10 µg/kg did elicit a 3-fold increase in 24-(OH)ase RNA levels (Fig. 3a, lanes 26-28). Potency comparisons between the various retinoids based upon their elicited efficacies (-fold inductions of RNA levels) are not possible without taking into consideration the complicated differences in bioavailability, metabolism, and excretion of the compounds in vivo.

While LG100268 is immaculately specific for RXR as assessed by both ligand binding assays (K(i)versus [^3H]9cRA for RXRs = 3 nM; for RARs >10 µM) and in cell-based cotransactivation assays ( (14) and see Fig. 4, lanes 1-4) to ensure that LG100268 was acting as an RXR-selective ligand in vivo in our system, Northern analysis was performed on the RARbeta gene product. RARbeta transcripts have been shown to be up-regulated by ligands that bind to RAR, but not by RXR-selective compounds, in F9 cells(8) . Fig. 3b shows that while 9cRA (lanes 9-12) and tRA (lanes 13-16) effect 1.5-2-fold increases in the levels of kidney RARbeta RNA, LG100268 does not (lanes 5-8). Therefore, LG100268 exhibits the properties of an RXR-selective compound in this system. Since RXR-selective (LG100268) and RAR-selective (TTNPB) compounds, as well as the endogenous retinoids 9cRA and tRA, increase 24-(OH)ase RNA levels, both RXR and RAR are able to participate in the induction of 24-(OH)ase.


Figure 4: Retinoids stimulate transcription from human 24-(OH)ase promoter sequences in the presence of retinoid receptors. RXR (lanes 1, 2, 5, 6, 10, and 12), RAR (lanes 3, 4, and 7), VDR (lanes 9 and 11), or RAR and RXR (lane 8) expression plasmids (13, 22) were cotransfected along with CRBPII (2, 22) (lanes 1 and 2), TRE-pal (22) (lanes 3 and 4), 24-(OH)-6000 (13) (lanes 5-8), 24-(OH)-400 (13) (lanes 9 and 10), or 24-(OH)-400)-1 (13) (lanes 11 and 12) containing reporter plasmids. -Fold induction was determined by dividing the normalized response (2, 22) at saturating concentrations of ligand by the normalized response with 10M ligand or with no added ligand.



Certain genes including apoA1 and CRBPII have been postulated to be activated through RXR-driven pathways by virtue of the fact that reporter plasmids driven by sequences from within their promoters have been shown to be stimulated by 9cRA or RXR-selective compounds in the presence of cotransfected RXR through a defined element in cell-based cotransactivation assays(2, 3, 4, 5, 6, 7) . However, since this initial work 4 years ago, there have not been any published reports showing that these genes are regulated in vivo. To test whether these genes are regulated in vivo in our system, Northern analyses were performed using RNA from liver (apoA1) and intestine (CRBPII) of the mice treated with two or five doses of the various retinoids for 8 or 32 h, respectively (Fig. 3c). ApoA1 (Fig. 3c, lanes1-16) and CRBPII (Fig. 3c, lanes 17-24) RNA levels did not change with retinoid treatment on the 8- or 32-h schedule in comparison with untreated animals. Therefore, in BALB/c mice under the conditions of these experiments no significant up-regulation of apoA1 and CRBPII was observed with retinoid treatment. Additionally, apoA1 RNA levels from rat liver also were not observed to change after dosing of rats with three different concentrations of RXR-selective compound for durations ranging from 4 h to 5 days. (^2)Therefore, to date, 24-(OH)ase is the only gene that has been shown to be regulated by RXR-selective ligands in the intact animal.

Circulating levels of LG100268 and 9cRA were determined by performing pharmacokinetic studies on mice treated with LG100268 or 9cRA. Two doses of 30 mg/kg LG100268, 3 mg/kg LG100268, or 10 mg/kg 9cRA were given 4 h apart, mice were sacrificed, and blood was obtained at various time points. Table 1shows that doses of 30 mg/kg LG100268 resulted in plasma concentrations of 1-13 µM LG100268 throughout the duration of the study. Ten-fold lower doses of LG100268 (3 mg/kg) effected the same -fold increase in 24-(OH)ase RNA levels as did higher LG100268 doses of 12 mg/kg (Fig. 3a) and 30 mg/kg (data not shown) and resulted in circulating LG100268 levels below the limits of quantitation of the assay (<250 nM). Doses of 10 mg/kg of 9cRA resulted in plasma concentrations of 100-600 nM 9cRA at the indicated time points. Ten-fold lower doses of 9cRA (1 mg/kg) also effected induction of 24-(OH)ase RNA (Fig. 3a); circulating levels were not measured at that dose. Therefore, the determined circulating levels of LG100268 and 9cRA after administration of effective doses for exertion of a biological effect (i.e. increase of 24-(OH)ase RNA) are in the low nanomolar range.

To ascertain if the observed increases in 24-(OH)ase RNA corresponded with an increase in kidney 24-hydroxylase enzyme activity, metabolic conversion assays were performed. Table 2shows that enzymatic conversion of 25-(OH)D(3) to 24,25-(OH)(2)D(3) in kidney extracts from mice treated with LG100268 (3 mg/kg twice daily for 8 h or 3.5 days) was 5-10-fold greater than the conversion observed in kidney extracts from normal untreated mice. The retinoids utilized in this study, including LG100268, are the only agents other than 1,25-(OH)(2)D(3) that have been shown to stimulate 24-(OH)ase activity. 1,25-(OH)(2)D(3) has been reported to increase 24-(OH)ase activity by 4-20-fold, depending on the species examined(25) . Therefore, the increase in kidney 24-(OH)ase RNA levels exerted by ligands that bind to RXR and RAR is reflected in a corresponding bioeffect, i.e. the kidney 24-(OH)ase enzymatic activity increases. Ultimately, elevated levels of 24-(OH)ase over time might be expected to decrease cellular concentrations of 1,25-(OH)(2)D(3), leading to reduced activity of VDR on its target genes, including 24-(OH)ase. This hypothesis is borne out by the inhibition by LG100268 of 1,25-(OH)(2)D(3)-induced 24-(OH)ase RNA levels after 8 days of treatment (Fig. 2a) and may provide a molecular basis for some of the accumulated observations over the past 50 years describing vitamin A effects on bone that mimic vitamin D deficiency conditions (26, 27, 28, 29, 30) and on other evidence showing a decrease in serum 1,25-(OH)(2)D(3) levels with high concentrations of vitamin A(30, 31, 32) .

To test whether the retinoids are able to stimulate transcription from 24-(OH)ase promoter sequences and to confirm that RXR is required for that activation, cotransfection experiments were performed in CV-1 cells with a promoterless luciferase vector containing human 24-(OH)ase promoter sequences(13) . Saturating concentrations of 9cRA or LG100268 elicited 7-10-fold inductions of luciferase activity in CV-1 cells that had been cotransfected with an expression vector producing RXR and a reporter plasmid containing 6 kb of 24-(OH)ase promoter sequence (13) (Fig. 4, lanes 5 and 6) while 1.5-2-fold induction was observed without transfected receptor, representative of endogenous RXR present in CV-1 cells (data not shown). 9cRA was also able to stimulate promoter activity in the presence of RAR (9-fold (Fig. 4, lane 7)) or RXR and RAR (14-fold (Fig. 4, lane 8)). 1,25-(OH)(2)D(3) induced transcription (10-fold) from a 400-bp 24-(OH)ase promoter sequence in the presence of VDR, as previously demonstrated (lane 9)(13) . This reporter was also activated by 9cRA in the presence of RXR (lane 10). A reporter vector with the 400-bp 24-(OH)ase promoter sequence containing three mutations in the upstream half-site of the vitamin D responsive element no longer binds to VDR, and the 1,25-(OH)(2)D(3)-induced transactivation through the promoter sequence is abolished (13) (Fig. 4, lane 11). 9cRA was able to stimulate luciferase activity in the presence of RXR via the mutant promoter (Fig. 4, lane 12) as well as it did through the wild type promoter sequence (Fig. 4, lane 10). Therefore, retinoid ligands acting through their respective receptors are able to stimulate transcription from the 24-(OH)ase promoter in a heterologous system utilizing cis element(s) that appear to be distinct from or overlapping with that utilized by VDR. Hence, effectors of vitamin A signal transduction, including the RXR-selective ligand, LG100268, acting through the nuclear retinoid receptors, induce a key gene involved in vitamin D signaling, thereby adding a new level of complexity to the cross-talk between the two systems.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Biochemistry, Ligand Pharmaceuticals, 10255 Science Center Rd., San Diego, CA 92121. Tel.: 619-550-7817; Fax: 619-625-7010.

(^1)
The abbreviations used are: RAR, retinoic acid receptor; tRA, all-trans-retinoic acid; RXR, retinoid X receptor; 9cRA, 9-cis-retinoic acid; CRBPII, cellular retinol-binding protein II; VDR, vitamin D receptor; 1,25-(OH)(2)D(3), 1,25-dihydroxyvitamin D(3); 24-(OH)ase, 25-hydroxyvitamin D(3)-24-hydroxylase; bp, base pair(s); kb, kilobase pair(s); GAPDH, glyceraldehyde-3-phosphate dehydrogenase; h, human; m, mouse; r, rat; HPLC, high pressure liquid chromatography.

(^2)
P. Syka, unpublished data.


ACKNOWLEDGEMENTS

We thank D. Mangelsdorf for critical discussions. We thank L. Zhang for assistance with LG100268 and S. White and J. Hebert for 9cRA. We thank S. Christakos, D. Shalinsky, C. H. Jin, G. Gillespie, and M. Shirley for helpful technical advice. The assistance of M. Elgort, K. Marschke, G. Croston, New Leads Discovery, P. Syka, R. Prudente, and L. Sheeter is appreciated. We thank Y. Ohyama for r24-(OH)ase cDNA.


REFERENCES

  1. Mangelsdorf, D. J., Umesono, K., and Evans, R. M. (1994) in The Retinoids (Sporn, M. B., Roberts, A. B., and Goodman, D. S., eds) pp. 319-349, Raven Press, New York
  2. Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., and Thaller, C. (1992) Cell 68,397-406 [Medline] [Order article via Infotrieve]
  3. Levin, A. A., Sturzenbecker, L. J., Kazmer, S., Bosakowski, T., Huselton, C., Allenby, G., Speck, J., Kratzeisen, C. I., Rosenberger, M., Lovey, A., and Grippo, J. F. (1992) Nature 355,359-361 [CrossRef][Medline] [Order article via Infotrieve]
  4. Mangelsdorf, D. J., Umesono, K., Kliewer, S. A., Borgmeyer, U., Ong, E. S., and Evans, R. M. (1991) Cell 66,555-561 [Medline] [Order article via Infotrieve]
  5. Rottman, J. N., Widom, R. L., Nadal-Ginard, B., Mahdavi, V., and Karathanasis, S. K. (1991) Mol. Cell. Biol. 11,3814-3820 [Medline] [Order article via Infotrieve]
  6. Lehmann, J. M., Jong, L., Fanjul, A., Cameron, J. F., Lu, X. P., Haefner, P., Dawson, M. I., and Pfahl, M. (1992) Science 258,1944-1946 [Medline] [Order article via Infotrieve]
  7. Boehm, M. F., Zhang, L., Badea, B., White, S. K., Mais, D. E., Berger, E., Suto, C., Goldman, M. E., and Heyman, R. A. (1994) J. Med. Chem. 37,2930-2941 [Medline] [Order article via Infotrieve]
  8. Davis, K. D., Berrodin, T. J., Stelmach, J. E., Winkler, J. D., and Lazar, M. A. (1994) Mol. Cell. Biol. 14,7105-7110 [Abstract]
  9. Perlmann, T., and Jansson, L. (1995) Genes & Dev. 9,769-782
  10. Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., and Mangelsdorf, D. J. (1995) Genes & Dev. 9,1033-1045
  11. Ohyama, Y., Noshiro, M., and Okuda, K. (1991) FEBS Lett. 278,195-198 [CrossRef][Medline] [Order article via Infotrieve]
  12. Ohyama, Y., Ozono, K., Uchida, M., Shinki, T., Kato, S., Suda, T., Yamamoto, O., Noshiro, M., and Kato, Y. (1994) J. Biol. Chem. 269,10545-10550 [Abstract/Free Full Text]
  13. Pike, J. W., Kerner, S. A., Jin, C. H., Allegretto, E. A., and Elgort, M. G. (1994) J. Bone Miner. Res. 9,S144
  14. Boehm, M. F., Zhang, L., Zhi, L., McClurg, M. R., Berger, E., Wagoner, M., Mais, D. E., Suto, C. M., Davies, P. J. A., Heyman, R. A., and Nadzan, A. M. (1995) J. Med. Chem., 38,3146-3155 [Medline] [Order article via Infotrieve]
  15. Li, H., and Christakos, S. (1991) Endocrinology 128,2844-2852 [Abstract]
  16. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162,156-159 [CrossRef][Medline] [Order article via Infotrieve]
  17. Benbrook, D., Lernhardt, E., and Pfahl, M. (1988) Nature 333,669-672 [CrossRef][Medline] [Order article via Infotrieve]
  18. Boguski, M. S., Elshourbagy, N., Taylor, J. M., and Gordon, J. I. (1985) Proc. Natl. Acad. Sci. U. S. A. 82,992-996 [Abstract]
  19. Li, E., Demmer, L. A., Sweetser, D. A., Ong, D. E., and Gordon, J. I. (1986) Proc. Natl. Acad. Sci. U. S. A. 83,5779-5783 [Abstract]
  20. Marchetti, M. N., Bun, H., Geiger, J. M., and Durand, A. (1994) Anal. Lett. 27,1847-1862
  21. Hollis, B. W. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,6009-6013 [Abstract]
  22. Allegretto, E. A., McClurg, M. R., Lazarchik, S. B., Clemm, D. L., Kerner, S. A., Elgort M. G., Boehm, M. F., White, S. K., Pike, J. W., and Heyman, R. A. (1993) J. Biol. Chem. 268,26625-26633 [Abstract/Free Full Text]
  23. Mangelsdorf, D. J., Ong, E. S., Dyck, J. A., and Evans, R. M. (1990) Nature 345,224-229 [CrossRef][Medline] [Order article via Infotrieve]
  24. Kurokawa, R., DiRenzo, J., Boehm, M., Sugarman, J., Gloss, B., Rosenfeld, M. G., Heyman, R. A., and Glass, C. K. (1994) Nature 371,528-531 [CrossRef][Medline] [Order article via Infotrieve]
  25. Engstrom, G. W., Reinhardt, T. A., and Horst, R. L. (1986) Arch. Biochem. Biophys. 250,86-93 [Medline] [Order article via Infotrieve]
  26. Wolbach, B. S., and Hegsted, M. D. (1952) A. M. A. Arch. Pathol. 54,30-38
  27. Wolke, R. E., Eaton, H. D., Nielsen, S. W., and Helmboldt, C. F. (1969) J. Pathol. 98,677-686
  28. Jowsey, J., and Riggs, B. L. (1968) J. Clin. Endocrinol. Metab. 28,1833-1835 [Medline] [Order article via Infotrieve]
  29. Clark, L. (1971) Aust. Vet. J. 47,568-571 [Medline] [Order article via Infotrieve]
  30. Frankel, T. L., Seshardri, M. S., McDowall, D. B., and Cornish, C. J. (1986) J. Nutr. 116,578-587 [Medline] [Order article via Infotrieve]
  31. Trechsel, U., and Fleisch, H. (1984) Calcif. Tissue Int. 36,S49
  32. Trechsel, U., and Fleisch, H. (1985) in Vitamin D, Chemical, Biochemical and Clinical Update (Norman, A. W., Grigoleit, H.-G., Schaefer, K., and Herrath, D. V., eds) pp. 51-52, Walter de Gruyter & Co., Berlin

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.